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ABSTRACT adb_301 1..10
Nicotine, the primary addictive component of tobacco, affects the mammalian brain. Smokers’ brains have smaller
cortical grey matter volumes and/or lower densities compared with non-smokers’. Differences in subcortical structures
like the striatum are however, less clear. A high concentration of nicotinic receptors makes the striatum a potential
target for nicotine. In addition, striatal nuclei are essential components of the reward/reinforcement pathway involved
in addiction. The aim of this study was to explore the relationship between striatal nuclei (caudate, putamen and
nucleus accumbens area) volumes and lifetime smoking in a large community-based sample of ‘young–old’ individu-
als. Brain volumes were measured using a semi-automated method in 315 participants aged 64–70 years who were
selected from a larger randomly sampled cohort and who consented to a magnetic resonance imaging scan. Multiple
regression analysis was used to assess the relationship between striatal volumes and cigarette smoking measures while
controlling for age, sex, intracranial and total brain volumes and general physical and mental health measures. Greater
lifetime use of cigarettes (measured in pack-years) was associated with smaller left nucleus accumbens area volume
(P = 0.018) and larger left putamen volume (P = 0.025). Greater putaminal volume was also associated with a lower
age at smoking initiation (P = 0.004). In this generally healthy cohort, lifetime use of cigarettes is significantly asso-
ciated with striatal volume measures. These changes could indicate predisposing factors for nicotine addiction, or an
effect of chronic nicotine exposure or a combination of both.
Keywords Brain volume, magnetic resonance imaging, nucleus accumbens, putamen, smoking.
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INTRODUCTION
Tobacco use in the form of cigarettes remains a signifi-
cant source of mortality/morbidity worldwide (Murray
2006). Despite increased awareness of its adverse effects,
tobacco use continues largely because of its highly addic-
tive nature. Among the hundreds of compounds present
in tobacco products, nicotine, an alkaloid produced by
the tobacco plant for its insecticidal effect, is primarily
responsible for this addictive property (Benowitz 1988).
Nicotine binds with highest affinity to neuronal nicotinic
acetylcholine receptors (nAChRs) (Whiting & Lindstrom
1988) and mimics the action of acetylcholine (Gaimarri
et al. 2007), a neurotransmitter endogenous to the
nervous system. In the central nervous system, nAChRs
are present both pre- and post-synaptically on different
neuronal subtypes and have a neuromodulatory function
(Gaimarri et al. 2007). This property of neuronal
nAChRs allows nicotine to have a secondary effect on
virtually all neurotransmitter/neuromodulator systems
in the brain (Evans & Drobes 2009). Thus it is not surpris-
ing that nicotine’s influence encompasses a wide range of
cognitive processes including sensory, motor, attention,
executive, learning and memory functions (Evans &
Drobes 2009). Repeated nicotine exposures comple-
mented by environmental cues produce lasting changes
in dopaminergic (DA) signals in the brain reward/
reinforcement centres resulting in addiction (Miyata &
Yanagita 2001).
Several functional imaging studies have reported
nicotine induced changes in human brain activation pat-
terns (Sharma & Brody 2009). However, anatomical and
neurochemical changes resulting from nicotine expo-
sure, evident in animals studies (Domino 2008), remain
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less explored in humans. In voxel-based morphometric
(VBM) studies greater lifetime exposure was correlated
with greater brain atrophy in elderly smokers (Longstreth
et al. 2000) and reduced cortical grey matter volumes/
densities in specific cerebral (e.g. frontal and temporal
lobes) and cerebellar regions in younger smokers (Brody
et al. 2004a; Gallinat et al. 2006). Group differences
in volume/densities in these brain regions were also
observed between smokers and non-smokers (Brody et al.
2004a; Gallinat et al. 2006). Gallinat et al. (2006) also
reported decreased grey matter volume/density in the
thalamus and substantia nigra (SN) in smokers.
Unlike animal studies in which the brain-damaging
effect of nicotine exposure is clearly evident, human
studies have failed to clarify whether the distinct features
of a smokers’ brain are predisposing factors for nicotine
addiction or the effects of chronic nicotine exposure, or
a combination of both (Brody et al. 2004a; Domino
2008). Nevertheless, it is interesting that the brain
regions reported to have reduced volume/density in
smokers also express a rich repertoire of nAChRs.
[3H]Nicotine binding studies revealed that in the human
brain nAChR density decreases in the following order:
thalamus > SN > striatum > cerebral cortex (Court et al.
2000). With the exception of the striatum, all these
structures were reported to be reduced in grey matter
volume/density in smokers (Brody et al. 2004a; Gallinat
et al. 2006). The striatum is a group of subcortical
nuclei and can be structurally divided into the caudate
(Cau), putamen (Put) and nucleus accumbens (NAc) (or
ventral striatum) (Fig. 1). As part of fronto-subcortical
neuronal circuits, the striatum plays a critical role in
planning, execution, and control of movement, acquisi-
tion of motor sequences, learning, reward processing,
cognitive functioning and addiction (Raz et al. 2003).
Previous studies compared only the ventral striatum [the
most important region for reward processing (Knutson
et al. 2000)] and found no significant differences in grey
matter volume/density between smokers and non-
smokers. Gallinat et al. (2006) commented that this
might indicate that smoking primarily affects cerebral
structures associated with inhibitory control of behav-
iour (e.g. the prefrontal cortex) than incentive drive (e.g.
the ventral striatum). Alternatively, methodological limi-
tation and small sample size could be the underlying
reason (Gallinat et al. 2006).
Owing to its role in the reward/reinforcement
pathway, the striatum is critical for the development of
nicotine addiction and with its high nAChR concentra-
tion also presents a potential target for nicotine. Further-
more, decrease in striatal nuclei volumes is detrimental
for normal brain function. Atrophy of striatal nuclei
occurs during normal ageing (Raz et al. 2003) and in
pathological conditions like Parkinson’s disease (PD)
(Geng, Li & Zee 2006). In healthy aged individuals
decrease in striatal nuclei volumes is associated with
severity of gait and balance problems (Rosano et al.
2007) while in PD patients, striatal nuclei atrophy is
Figure 1 Three-dimensional model of the
human brain indicating the position of the
striatal nuclei. (a) Saggital view of the model
superimposed on the magnetic resonance
imaging image of head (c) anterior view.
Magnified images showing only striatal
structures in the saggital (b) and anterior
(d) views, respectively. Caudate is indicated
in blue, putamen in pink and nucleus
accumbens area in yellow
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correlated to the severity of clinical symptoms (Geng
et al. 2006). In this study we explore the relationship
between cigarette use and striatal nuclei volumes in a
community-based sample of healthy individuals aged
between 64 and 70 years. We are unaware of any previ-
ous report that has explored the relationship between
these critical subcortical structures and nicotine expo-
sure in a large non-clinical sample in this age group.
METHODS AND MATERIALS
Participants
The study sample was drawn from the PATH Through Life
Project designed to investigate the risk and protective
factors for normal ageing, dementia and other neuropsy-
chiatric disorder (Jorm et al. 2004) in three age groups
(20–24, 40–44, 60–64) of randomly selected individuals
who were residents of the city of Canberra and the
adjacent town of Queanbeyan, Australia, and to be
followed-up every 4 years for 20 years. Participants were
recruited randomly from the electoral roll, which provides
a good representative population sample because enrol-
ment to vote is a legal requirement for all adult Australian
citizens. The study was approved by the ethics committees
of The Australian National University and The University
of New South Wales. All participants gave written
informed consent to be included in the PATH project. The
present study was focused on the older cohort at the
second wave of data collection, which included 2222 indi-
viduals aged 64–70 years. During the interview partici-
pants provided information about age, sex, years of
education, occupation, smoking, substance use, medical,
psychiatric, medication history, etc. A randomly selected
subsample of 622 participants was offered a magnetic
resonance imaging (MRI) scan, which 478 eventually
completed. Of those 431 participants took part in the
second wave of data collection and after exclusions for a
history of stroke (n = 8), cognitive impairments (n = 12),
and poor scan quality or missing data for the variables
used in statistical analyses (n = 96), 315 participants were
available for this investigation. The sample for which MRI
data was available (MRI+) did not differ significantly from
the remaining cohort (MRI-) in any of the demographic
and smoking variables except for years of education
(P = 0.032) and total years of smoking (P = 0.014). The
MRI+ sample had greater mean years of education and
lower mean total years of smoking.
MRI acquisition
MRI data were acquired on a 1.5 Tesla Gyroscan scanner
(ACS-NT, Philips Medical Systems, Best, the Nether-
lands). T1-weighted 3-D structural MRI images were
acquired in coronal plane using Fast Field Echo (FFE)
sequence. The scanning parameters were TR = 8.84 ms,
TE = 3.55 ms, a flip angle of 8°, matrix size = 256 ¥ 256,
slices 160, and the field of view (FOV) 256 ¥ 256 mm.
Slices were contiguous with slice thickness of 1.5 mm.
Image analysis
Volumetric segmentation was performed with the
Freesurfer image analysis suite, which is documented
and freely available for download online (http://
surfer.nmr.mgh.harvard.edu/). This processing includes
motion correction, removal of non-brain tissue using
a hybrid watershed/surface deformation procedure
(Ségonne et al. 2004), automated Talairach transforma-
tion, and segmentation of the subcortical structures
(including hippocampus, amygdala, Cau, Put, NAc area,
ventricles) (Fischl et al. 2002, 2004).
Cigarette smoking measures
Participants reported on cigarette use by answering ques-
tions such as, ‘Do you currently smoke?’, ‘Have you ever
smoked regularly?’, ‘On an average how many cigarettes
you have smoked each day over the time you were
smoking?’, ‘At what age did you start smoking?’ and ‘At
what age did you stop smoking?’. Based on their smoking
history participants were grouped as non-smokers (cur-
rently not smoking and never smoked regularly) or
smokers (including current and ex-smokers). Average
number of cigarettes smoked per day (CPD) over the time
smoked and age at which smoking started were used to
compute total years of smoking and pack-years. Four
continuous smoking variables—pack-years, CPD, total
years of smoking and age at start of smoking and
one categorical variable—smoking status (non-smoker
versus smoker) were used in this study. For regression
analysis, pack-years, CPD and total years of smoking
were entered as continuous variables, with non-smokers
having a value of zero.
Brain volume measures
All brain volume measures were entered as continuous
variables. Whole-brain measures used were—
intracranial volume (ICV), total brain volume (TBV) and
total ventricular volume (TVV). Striatal nuclei (Cau, Put
NAc) volumes used were uncorrected raw volumes mea-
sured separately for left and right hemispheres.
Statistical analysis
All statistical analyses were conducted using SPSS 18
(SPSS Inc., Chicago, IL, USA). Means and standard
deviations were computed for all continuous variables
of interest. Comparisons between ‘non-smoker’ and
‘smoker’ categories were performed using Student’s t-test
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for continuous variables and Pearson’s c2-square test for
categorical variables. Association of each of the continu-
ous cigarette smoking measures (dependent variables)
and whole-brain measures or striatal nuclei volumes
(independent variables) were assessed by multiple regres-
sion while controlling for covariates (age, sex). Cigarette
smoking can be affected by a number of factors including
education level, physical health and mental health disor-
ders like anxiety and depression (Lawrence, Mitrou &
Zubrick 2009). Hence, in addition to age and sex, we
included years of education, physical health [RAND-12
physical health scale (Hays, Prince-Embury & Chen
1998)], diabetes and hypertension status, and symptoms
of anxiety and depression [Goldberg’s scale (Goldberg
et al. 1988)] as covariates. The inclusion or exclusion of
the health variables mentioned above did not alter results
of the analyses significantly. Regression models with the
health variables included as covariates are reported. As
the striatal nuclei volumes used in the analysis were
uncorrected raw volumes, we also controlled for ICV and
TBV. Analysis of age of smoking initiation was performed
for the ‘smoker’ category only, after controlling for age,
sex, ICV and TBV. A high prevalence of comorbid chronic
smoking and alcohol dependence has been reported
(Meyerhoff et al. 2006) and chronic alcohol dependence
is associated with smaller brain volumes (Makris et al.
2008). We therefore carried out additional regression
analyses where we included variables for alcoholic drink
consumption. Interaction effects of striatal nuclei
volumes ¥ sex and striatal nuclei volumes ¥ alcoholic
drink consumption were also tested. In regression analysis
the covariates were entered in the model first, followed by
the predictors and then the interactions terms. Change in
R2 value between the two models and the P value associ-
ated with the R2 change were noted. Predictors with
P > 0.10 were progressively removed to generate a
reduced model. The threshold of significance was set at
P = 0.05. As none of the interaction terms contributed
significantly models including interaction terms are not
reported.
RESULTS
Smoker and non-smoker groups were similar in age, edu-
cation level, physical health scores, prevalence of hyper-
tension, diabetes and anxiety/depression symptoms
(Table 1). There were significant differences in sex ratio
between the two groups, with a higher proportion of
women being non-smokers (P = 0.002). Smokers also
consumed significantly (P < 0.001) higher amounts of
alcoholic drinks per week. For the brain volume mea-
sures (Table 2), smokers had significantly higher ICV
(P = 0.029), TBV (P = 0.042) and TVV (P = 0.005) while
Cau, Put and NAc volumes were similar in both groups.
The apparent difference in ICV between smokers and
non-smokers disappeared after correcting for sex.
However, significant (P < 0.05) differences in TBV and
TVV remained after correcting for sex and ICV with
smokers having smaller TBV and larger TVV compared
with non-smokers.
Table 1 Demographic characteristics and cigarette use history of smokers and non-smokers (Mean  SD for continuous variables
and frequency for categorical variables shown).
Smoker (n = 123) Non-smoker (n = 192) d.f. t/c2 P
Age (years) 66.5  1.5 66.7  1.4 313 1.165 0.245
Sex
Male 77 86 1 9.524 0.002**
Female 46 106
Education (years) 14.5  2.6 14.2  2.7 313 -0.848 0.397
RAND-12 physical health
(Hays et al. 1998)
49.49  9.49 49.92  9.33 313 0.415 0.678
Diabetes 12 (9.76%) 18 (9.38%) 1 0.005 0.945
Hypertension 57 (46.43%) 85 (44.27%) 2 0.411 0.814
Goldberg’s anxiety score
(Goldberg et al. 1988)
2.42  2.87 2.26  2.23 313 -0.602 0.548
Goldberg’s depression score
(Goldberg et al. 1988)
1.77  1.87 1.73  1.87 313 -0.176 0.861
Alcoholic drinks/week 10.6  10.4 5.7  7.4 313 -4.924 <0.001**
Pack-years 26.42  25.67
CPD 19.2  13.4
Years of smoking 25.7  14.0
Age at start of smoking 18.7  5.85
t-tests were performed for continuous variables and c2 tests for categorical variables; *Significant at 0.05 level; **Significant at 0.01 level; CPD = Cigarette
per day.
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Means and standard deviations of the cigarette
smoking measures—(1) magnitude of lifetime use of
cigarettes or pack-years; (2) average number of cigarettes
consumed per day (CPD); (3) total years of smoking; (4)
age at start of smoking are given in Table 1. We assessed
associations between the cigarette use and whole-brain
(TBV and TVV) or striatal nuclei volumetric measures by
multiple regression while controlling for covariates (see
Methods). TBV was negatively and TVV positively associ-
ated with pack-years, CPD and total years of smoking
(Table 3). No significant associations were observed
between age at start of smoking and either of the whole-
brain volume measures (Table 3).
Results of regression analyses with smoking measures
as dependent variables and Cau, Put, NAc volumes as
predictors are presented separately for the left and right
hemispheres (Table 4). Significant associations were
observed only for left hemispheric volumes, which are
described below. After controlling for covariates, NAc and
Put but not Cau volumes were significantly associated
with lifetime use of cigarettes. After progressively remov-
ing variables that did not reach statistical significance,
only NAc volume remained as a significant predictor in
the reduced model. The association between lifetime use
and NAc volume was negative, indicating that heavier
cigarette consumption correlated with smaller NAc
volume. The pack-year measure of lifetime use includes
measures of average daily cigarette use (CPD) and dura-
tion (total years of smoking behaviour), both of which
independently showed a trend towards a negative asso-
ciation with NAc volume but failed to reach significance
(Table 4).
In contrast, the association between lifetime use and
Put volume was positive, indicating a correlation of
greater use with higher Put volume. CPD and total years
of smoking also exhibited positive correlations with Put
volume but did not reach statistical significance (P > 0.1).
In smokers, larger left hemispheric Put volume was sig-
nificantly associated with a lower age at smoking initia-
tion (Table 4). A similar trend was observed for the right
hemispheric Put volume, which did not reach statistical
significance (P = 0.063).
Although alcoholic drinks used per week was nega-
tively associated (b = -0.019, P < 0.001) with TBV, the
associations between striatal nuclei volumes and ciga-
rette smoking variables described above did not change
significantly after controlling for alcoholic drink con-
sumption. Smoking status (non-smoker versus smoker)
Table 2 Brain measures (raw volumes) of smokers and non-smokers (mean  standard deviation).
Smoker (n = 123) Non-smoker (n = 192) d.f. t P
ICV (litres) 1.56  0.18 1.52  0.18 313 -2.197 0.029*a
TBV (litres) 1.53  0.18 1.49  0.17 313 -2.043 0.042*b
TVV (litres) 0.034  0.002 0.028  0.001 313 -2.817 0.005**b
N Accumbens volume (ml)
Left 0.50  0.10 0.51  0.09 313 0.881 0.379
Right 0.54  0.08 0.53  0.08 313 -0.625 0.533
Putamen volume (ml)
Left 4.89  0.64 4.77  0.60 313 -1.657 0.098
Right 4.89  0.66 4.75  0.58 313 -1.863 0.063
Caudate volume (ml)
Left 3.36  0.53 3.29  0.48 313 -1.172 0.242
Right 3.70  0.59 3.64  0.53 313 -1.051 0.294
aNot significant after corrected for sex; bsignificant after corrected for sex; *Significant at 0.05 level; **Significant at 0.01 level; ICV = intracranial volume;
TBV = total brain volume; TVV = total ventricular volume.
Table 3 Multiple regression models for smoking measures with TBV or TVV as predictors.
Cigarette use
variables
TBV TVV
Beta (P) R2 (change) P Beta (P) R2 (change) P
Pack-yearsa -2.648 (0.000) 0.125 (0.037c) 0.000 0.243 (0.000) 0.125 (0.037c) <0.001
CPDa -2.312 (0.002) 0.136 (0.028c) 0.002 0.213 (0.002) 0.136 (0.028c) 0.002
Years of smokinga -2.309 (0.003) 0.064 (0.028c) 0.002 0.211 (0.004) 0.063 (0.027c) 0.004
Age at startb -0.474 (0.662) 0.050 (0.002) 0.662 0.050 (0.648) 0.050 (0.002) 0.648
aControlled for age, sex, education, physical and mental health measures, intracranial volume; bControlled for age, sex, intracranial volume; c0.05
Significant R2 change from model with only covariates as predictors; TBV = total brain volume; TVV = total ventricular volume.
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was significantly associated with TBV (b = -0.010,
P = 0.017) and TVV (b = 0.111, P = 0.018) after control-
ling for age, sex, education and health covariates but not
with any of the striatal measures.
DISCUSSION
This study detected significant associations between
brain volumes and measures of cigarette smoking. We
found significant correlations between whole-brain
volumes and smoking history. Our results suggest that
as lifetime cigarette use increases, TBV decreases with
concomitant increase in the volume of brain ventricles.
Among the striatal nuclei, significant associations with
smoking measures were observed only for left hemisphere
with smaller NAc and larger Put volumes associated with
greater lifetime cigarette use. NAc volume explains 1.3%
of the variance in pack-years in our sample. The relation-
ship between NAc volume and pack-years was not
observed in two earlier studies (Brody et al. 2004a; Galli-
nat et al. 2006). One possible reason for this is that our
study sample size is significantly larger than that of the
previous studies. We observed interesting relationships
between Put volume and lifetime use of cigarettes and age
at start of smoking, which have not been reported in any
previous study that we are aware of. Larger left hemi-
spheric Put volume was associated with greater lifetime
cigarette use and a lower age of smoking initiation. Age at
which smoking is initiated has a large impact on future
smoking behaviour. Early initiation was reported to be
associated with increased nicotine dependence, greater
consumption, longer duration and lower quitting rates
(Khuder, Dayal & Mutgi 1999).
In the absence of information on brain volume mea-
sures prior to smoking onset, it is not possible to infer the
causal relationships between brain volume measures and
cigarette use from these associations. However, our result
suggesting association between smaller brain volume
and greater pack-years is in line with previous reports on
increased brain atrophy in smokers (Longstreth et al.
2001). In the context of striatal nuclei, a small NAc and
a large Put (relative to the whole brain) might indicate
vulnerability to nicotine addiction. Conversely, given
the evidence supporting the effect of nicotine on the
mammalian brain, these features might represent conse-
quences of chronic nicotine exposure. Longitudinal
imaging studies tracking smokers during years of active
smoking are required to distinguish definitely between
these alternatives.
Irrespective of the direction of causality, our finding
that NAc volume was negatively associated with lifetime
use of cigarettes provides evidence supporting the impor-
tance of the NAc in nicotine addiction pathway, as sug-
gested in previous studies (Wise & Bozarth 1987; KoobTa
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1992; Balfour 2004). According to the psychomotor
stimulant theory of addiction (Wise & Bozarth 1987), the
ability to activate the DA neurons of the ventral tegmen-
tal area (VTA) is a characteristic property of all drugs of
abuse and is fundamental to their ability to cause depen-
dence. This activation results in a surge of dopamine in
the NAc, the primary recipient of the VTA DA terminals
(Balfour 2004). Substantial evidence from animal studies
demonstrates that nicotine-induced dopamine release in
the NAc underlies the reinforcing properties of nicotine
addiction (Koob 1992). Positron emission tomography
imaging has demonstrated increased dopamine release in
human NAc during smoking (Brody et al. 2004b). Thus
structural differences in this nucleus might represent fea-
tures of chronic smoking.
The positive correlation between smoking measures
and Put volume is in contrast to the trend observed for
total brain and other striatal nuclei volumes. Again in the
absence of any information on brain volume measures
prior to smoking onset, there can be at least two possible
explanations for these observations: (1) individuals with
larger Put volumes are more likely to become heavy
smokers or start smoking at a younger age; (2) greater
nicotine exposure owing to greater use or an earlier start
protects against age-related putaminal atrophy, so that
Put volume declines less in heavy smokers and thus
becomes relatively larger compared with non-smokers as
they age. While the importance of the Put in development
of nicotine addiction is not clear, a neuroprotective role of
nicotine is indicated in studies of PD.
A characteristic feature of PD is a selective loss of DA
neurons in the SN and loss of dopamine in the striatum
resulting in severe motor dysfunction (Shimohama
2009). Putaminal atrophy, evident even prior to any sig-
nificant loss of SN volume, correlates with severity of
motor deficits (Geng et al. 2006). Epidemiological studies
suggested that cigarette smoking is associated with a
decreased risk of developing PD (Quik et al. 2009). It is
believed that the possible neuroprotective ability of nico-
tine underlies the negative relation between smoking and
PD (Picciotto & Zoli 2008). A neuroprotective effect of
nicotine has also been demonstrated on cultured neurons
and animal models (Picciotto & Zoli 2008). Both in the
rodent and primate Parkinsonian models, nicotine treat-
ment improved function of the lesioned striatum (Quik
et al. 2009). Moreover, the presence of nicotine prior to
but not after damage is neuroprotective (Huang et al.
2009). This lends support to the observation that the
protective effect of smoking is highest in continuing
smokers and progressively decreases in ex-smokers with
increasing years after quitting (Ritz et al. 2007).
Nicotine has both protective and toxic effects on
neurons and different classes of neurons appear to be
differentially affected by its damaging and protective
properties. The net outcome of nicotine exposure is thus
specific to the neuronal subtype. This could be partly
mediated by the brain-region specific expression of
nAChR subtypes. The neuroprotective effect of nicotine
was shown to be mediated primarily by the a-6 contain-
ing nAChR subtype (Huang et al. 2009), which is
expressed in high levels in the SN, VTA and striatum
(Gaimarri et al. 2007). Hence in the background of
global grey matter decrease resulting from nicotine expo-
sure (Longstreth et al. 2000, 2001), some brain regions,
such as the Put could benefit from the neuroprotective
effect of nicotine. It is important to note in this context
that in our study Put volumes of smokers only appear
relatively larger when brain size is controlled for. This
pattern is consistent with protection of the Put from the
greater general atrophy that occurs in the brains of heavy
smokers.
We observed significant associations only for the left
hemisphere. Previous studies have shown that the left
hemisphere is more specialized than the right in
approach (as distinct from avoidance)-related behaviour,
which includes smoking (Demaree et al. 2005). Also,
smoking-induced dopamine release is significantly higher
in the left, but not the right ventral striatum (Brody et al.
2004b). Thus, irrespective of whether striatal nuclei
volume differences are predisposing factors or outcomes,
the left hemisphere is likely to be more important in
smoking-related behaviours.
Although we found a significant relationship between
brain volumes and lifetime use of nicotine, measured in
pack-years and treated as a continuous variable, we did
not detect the differences in striatal volumes between
smoker and non-smoker categories that have been found
in other studies (Brody et al. 2004a; Gallinat et al. 2006).
We believe this is because of a less stringent definition of
a ‘smoker’ used in our study. In earlier studies, only nico-
tine dependent current smokers were included in the
study. As both ex-smokers and current smokers were
included in our study, this category had a much broader
distribution of nicotine exposures compared with previ-
ous studies.
This study has many strengths as well as several limi-
tations. The present investigation was conducted in a
cohort based on a larger random sample of the popula-
tion and it was larger than most studies conducted to date
on this topic. Therefore, the present results are more likely
to be generalizable. Also, similar findings were found for
different measures of smoking behaviour, which suggest
that these relationships are reliable and stable. Limita-
tions are that in absence of additional information on age
of daily smoking, significant abstinence periods or major
changes on cigarette use, the pack-years variable is an
imprecise measure of lifetime cigarette use. Smoking was
assessed by self-report, which therefore may not be
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perfectly accurate. Other factors associated with smoking
behaviours such as personality, mood disorders, and
physical health may partly underlie the current results.
With this in mind we have been particularly careful in
controlling for relevant covariates such as physical and
mental health status, socio-demographic variables and
alcohol consumption. As with alcohol, abuse of other
drugs also affects brain structure and is frequently comor-
bid with cigarette use. Although we collected data on
marijuana, ecstasy and amphetamine use, we could not
analyse the effect of such comorbid substance abuse in
our sample as too few individuals reported use of these
drugs. With respect to our study sample, it is possible that
the MRI sub-sample might not be as representative of the
population as the original random sample from which it
was derived. However, as the mean total years of smoking
(the only smoking variable significantly different between
the two samples) of the MRI sub-sample was lower, this is
likely to have decreased and not increased the magnitude
of associations we observed. Given the explanatory
nature of this study and the controversy regarding cor-
rection for multiple comparisons (Rothman 1990) we
chose to report the uncorrected P values. Hence our
analysis needs to be replicated in other samples.
In conclusion, this study provides evidence of associa-
tions between striatal nuclei volumes and cigarette
smoking. Left hemispheric NAc volume was negatively
associated with lifetime use of cigarettes. In contrast, a
positive association was observed between left hemi-
spheric Put volume and pack-years and age at start of
smoking. Whether these differences in brain structures
predispose individuals towards nicotine addiction or are
effects of chronic stimulation with nicotine (and/or other
chemicals found in tobacco products) remains to be
examined.
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